Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.43 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801767 | 0.89 | SPR (0.47) | SPRMGLLMAPK14TRPV1FASN | |
| SCHEMBL2801029 | 0.89 | SPR (0.41) | SPRMGLLFASNTPSAB1AVPR1A | |
| SCHEMBL2801492 | 0.87 | SPR (0.45) | SPRMGLLMAPK14TRPV1TPSAB1 | |
| SCHEMBL2802343 | 0.87 | JAK2 (0.38) | SPRMGLLFASNTPSAB1ALDH1A1 | |
| SCHEMBL2802212 | 0.86 | SPR (0.41) | SPRMGLLMAPK14FASNAVPR1A | |
| SCHEMBL2801510 | 0.86 | EGLN1 (0.38) | SPRFASNALDH1A1OPRM1SIRT5 | |
| SCHEMBL2803213 | 0.86 | NPC1 (0.40) | SPRFASNALDH1A1OPRM1SIRT5 | |
| SCHEMBL2801629 | 0.86 | MGLL (0.42) | SPRMGLLTPSAB1ALDH1A1 | |
| SCHEMBL2800919 | 0.86 | ALDH1A1 (0.38) | SPRFASNTPSAB1HTR2BALDH1A1 | |
| SCHEMBL2801964 | 0.86 | SPR (0.40) | SPRMGLLMAPK14FASNAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | SPR 2955/4885MGLL 4369/4885MAPK14 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.